💨 Abstract

The European Medicines Agency has recommended the approval of a twice-yearly HIV prevention drug, lenacapavir. This drug, sold as Yeytuo by Gilead Sciences, has shown nearly 100% effectiveness in preventing HIV transmission. The European Commission's acceptance will validate the drug across the EU and associated countries. The World Health Organization and the U.S. FDA have also approved it, but accessibility concerns persist, particularly in regions with increasing HIV rates.

Courtesy: WTOP Staff